Diversity of Neisseria meningitidis invasive isolates in Italy in the period 2008-2010 by Neri, A et al.
109
J prev med hyg 2012; 53: 109-112
Introduction 
Neisseria meningitidis, is the aetiological agent of invasive 
meningococcal disease (IMD), characterized by two main 
clinical pictures: meningitis and sepsis. Meningococcal 
disease occurs worldwide in both endemic and epidemic 
forms. Humans are the only natural reservoir of menin-
gococcus. As many as 10% of adolescents and adults are 
asymptomatic transient carriers of N. meningitidis, most 
strains of which are not pathogenic [1]. Of the 13 rec-
ognized meningococcal serogroups, 5 (A, B, C, Y, and 
W135) are responsible for the majority of the disease [2].
The epidemiology of meningococcal disease varies 
across the world [3]. In Europe and other industrialized 
countries, serogroups B and C are the major causes of 
invasive meningococcal disease with serogroup B pre-
dominantly isolated from individuals under 20 years of 
age. The annual incidence of confirmed cases of inva-
sive meningococcal disease ranges from 0.13 to 3.01 per 
100,000 inhabitants in different countries [4].
In Africa, serogroups A and X are the most frequently 
found as responsible of invasive meningococcal diseas-
es [5]. 
Currently, different vaccine formulations using polysac-
charides are able to prevent meningococcal cases of se-
rogroups A, C, Y and W135, but not against serogroup 
B, since the B polysaccaride resembles the human neu-
ral cell adhesion molecules, resulting in poor immuno-
genicity response. Surface-exposed protein antigens, 
GNA2132 or Neisserial heparin-binding antigen (NH-
BA) fused with GNA1030, GNA2091 fused with factor 
H binding protein (fHbp), Neisserial adhesin A (NadA), 
and outer membrane vesicles (OMV), are the compo-
nents of the next generation vaccines against serogroup 
B meningococci, under registration and of next release 
in the market [6]. 
Italy is currently one of the European countries with the 
lowest incidence, about 0.3 cases per 100,000 inhabit-
ants per year [7]. The two main serogroups are B and C, 
with an increase of serogroup B since 2006.
The present study refers data collected from 2008 
through 2010 describing the phenotypic and genotypic 
characteristics of meningococci from invasive disease. 
Changes in predominant serogroups and genotypes of 
meningococci are also here described.
Materials and methods
All strains received at the National Reference Labora-
tory (NRL) of the Istituto Superiore di Sanità were sub-
cultured to confirm the serogroup by slide agglutination 
with commercial antisera (Remel Europe, Ltd, UK). Se-
rotypes and serosubtypes were determined by standard 
whole-cell ELISA with monoclonal antibodies (pur-
chased from NIBSC, UK) [8].
Susceptibility MIC values for penicillin, rifampicin, cip-
rofloxacin, and ceftriaxone were determined by Etest 
method (bioMérieux, Italy), according to the manufac-
turer’s instructions.
The breakpoints were those in agreement with EUCAST 
breakpoints, version 2.0, January 1, 2012 [9].
Molecular characterization by MLST (Multilocus Se-
quence Typing), and porA VRs (Variable Region) typ-
ing, were performed on 188 meningococci isolated in the 
study period. Primers, determination of sequence alleles 
and designation of sequence types were those described 
on the MLST website [10, 11]. Variable regions (VRs) 1 
and 2 were submitted to the N. meningitidis PorA vari-
able regions database [12]. 
All data were managed and analyzed with Epi-Info ver-
sion 3.3.2.
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In the period 2008-2010, 309 Neisseria meningitidis, isolated in 
Italy within the National Surveillance of the Invasive Meningococ-
cal Diseases, have been tested for their phenotypic and genotypic 
characteristics. The main results obtained are: (a) an increase of 
the strains of serogroup B and a decrease of serogroup C; (b) a 
phenotypic and genotypic variability of the ST-41/44 clonal com-
plex, the most frequently isolated among serogroup B strains; (c) 
a decrease of ST-8 clonal complex among serogroup C menin-
gococci whereas strains belonging to ST-11 clonal complex are 
nowadays the most frequently isolated. 
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Within the National Surveillance System of Invasive 
Meningococcal Diseases, the NRL received 60% of all 
N. meningitidis strains isolated by local hospital labora-
tories from January 2008 through December 2010.
Phenotypic characterization
A total of 167 strains were serogroup B, 103 serogroup 
C, 20 serogroup Y, 11 serogroup W135, 4 serogroup 
A, 1 serogroup X, and three were non-serogroupable. 
Figure 1 shows the distribution of serogroups by years. 
Serogroup B replaced serogroup C since 2006 and the 
proportion increased up to 58.7% in 2010, while, sero-
group C decreased to 24%. 
A significant increase in serogroup Y isolates has been 
also observed over the last three years (2.8% in 2008 vs 
12% in 2010).
The most common phenotypes identified within se-
rogroup B isolates were: B:15:P1.4 (14.6%) and 
B:NT:P1.14 (7.1%).
Among serogroup C the most common phenotypes iden-
tified were: C:2a:P1.5 (31.1%), C:2b:P1.2,5 (14.6%) and 
C:NTNST (9.7%). 
A total of 275 meningococci were analyzed for the anti-
microbials susceptibility. All isolates were susceptible 
to ceftriaxone; 3 isolates were resistant to rifampicin 
with MIC = 32 mg/L; 2 were resistant to ciprofloxa-
cin with MIC = 0.19 mg/L and MIC = 0.064 mg/L, 
respectively. Notably, the 46.5% of the meningococci 
showed a reduced susceptibility to penicillin with a 
MIC range of 0.094-0.19 mg/L and one isolates was 
resistant (MIC = 0.5 mg/L) according to the most re-
cent breakpoint [9].
Genotypic analysis
Table I summarizes the molecular characterization of 
188 meningococci. MLST revealed a total of 17 already 
known clonal complexes (ccs) and 56 different Sequence 
Types (STs). The ST-41/44 cc was the most common, 
with 24 different STs and 62 (96.8%) serogroup B iso-
lates. This clonal complex remained stable among sero-
group B (55%) from 2008 through 2010. 
The ST-11 cc was the most important among serogroup 
C (36 isolates out of 38) during the 3 years period (Tab. 
I). The ST-8 cc and the ST-334 cc were identified exclu-
sively among serogroup C isolates. In particular, ST-8 
cc is one of the most common identified until 2008, and 
then it decreased in favour of others clonal complexes as 
the ST-334 cc, accounting for 30.8% of the serogroup C 
isolates.
MLST showed the highest heterogeneity among sero-
group B (Tab. I). Moreover, ST-865 cc and ST-162 cc 
have been rapidly increased: from 3% in 2008 to 7% in 
2010, and from 6% in 2008 to 9.5% in 2010, respec-
tively (data not shown). 
The ST-23 cc was predominant among serogroup Y 
strains whereas only 1 serogroup Y strain belongs to 
ST-167 cc (Tab. I).
The P1.7-2,4 PorA variants represented the 36% of sero-
group B strains belonging to ST-41/44 cc and P1.5,2 PorA 
variants represented the 39.4% of serogroup C/ ST-11 cc.
Fig. 2. percentage of phenotypes belonged to serogroups B and 
C meningococci isolated in italy from 2008 to 2010.
Fig. 1. distribution of meningococcal serogroups detected from 
imd cases from 2008 to 2010.
diversity OF Neisseria meNiNgitidis iNvasive isOlates iN italy
111
Discussion
Invasive infections caused by N. meningitidis are a seri-
ous public health problem worldwide, given the ability 
to spread easily and quickly. Public health management 
of the disease requires bacterial typing information, by 
knowing the epidemiological and microbiological char-
acteristics of strains isolated throughout the country.
Meningococcal disease is characterized by a remark-
able variation in the incidence and serogroup distribu-
tion [13]. Although the incidence of IMD in Italy has 
been reported of a mean value of 0.27 per 100,000 in-
habitants [7], meningococcal serogroups showed a dy-
namic evolution. Generally, meningococcal serogroups 
define a change between C and B serogroups every 3-4 
years. What we observed in the last 3 years was a rap-
idly decline of serogroup C meningococci probably 
due to the primary vaccination of infants adopted by 
the majority of the Italian Regions (17 of 21) [14]. 
As reported in the U.S.A. [15] and England [16], sero-
group Y increased significantly; this trend was also ob-
served in Italy accounting for 2.8% in 2008 and 12% in 
2010. 
Typing results of the Italian strains showed a wide range 
of phenotypes among serogroup B compared to sero-
group C. In particular, the two most prevalent pheno-
types were B:15:P1.4, as the predominant since 1999, 
and B:NT:P1.14, more recently identified [17]. 
The majority of serogroup C were C:2a:P1.5,2. These 
strains were hyper-endemic and responsible for an in-
creased number of fatal cases of septicemia and for 
two clusters of IMD in young adults in the North of 
Italy [18]. In addition, the results revealed a proportion 
of strains belonging to C:NT:NST (9.7%), suggesting a 
lower power of discrimination of the monoclonal com-
mercial antibodies possibly due to recent changes of 
these surface proteins.
We found a strong association between some clonal 
complexes and serogroups, as reported in previous 
studies [13]. ST-41/44 cc was significantly associated 
with serogroup B, while the ST-23 cc showed a strong 
association with serogroup Y. It is also worth mention-
ing that serogroup C meningococci, belonging to ST-
11 cc is the most frequently identified (61%) which 
has replaced the previously predominant ST-8 clonal 
complex (23%). 
PorA type P1.7-2,4 was detected in 36% of serogroup B 
meningococci which show a high variability.
Few cases due to resistant strains to ciprofloxacin and 
rifampicin have been found and almost half of strains 
(46.5%) showed a reduced susceptibility to penicillin. 
Although rifampicin is the antibiotic of choice in the 
prophylaxis of close contacts there is a very low rate of 
resistance reported in the literature [19, 20].
The results of the present study suggest that a careful mon-
itoring of phenotypical and genotypical changes among 
the circulating meningococci is required, especially after 
the introduction of MenC vaccine and before the intro-
duction of MenB vaccines in the country.
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Tab. I. distribution of clonal complexes within 188 invasive meningococcal isolates collected from 2008 through 2010 in italy.
Clonal complex No. of STs No. of isolates Serogroup(s) (no. isolates)
Most common PorA typea
(no. of isolates)
st-41/44 24 64 B(62) C(1) y(1) p1.7-2, 4 (23)
st-11 1 38 C(36) B(1) W135(1) p1.5, 2 (15)
st-8 2 14 C(14) p1.5, 2 (7)
st-32 6 12 B(12) heterogenous
st-23 3 11 y(11) p1.5-2, 10-2 (4)
st-162 1 9 B(9) p1.22, 14 (9)
st-269 5 7 B(6) C(1) p1.19-1, 15-11(3)
st-334 1 6 C(6) p1.7-4, 14-6 (6)
st-461 2 5 B(5) heterogenous
st-865 1 5 B(5) p1.21, 16-36(2)
st-22 2 5 W135(5) p1.18-1, 3(5)
st-5 2 4 a(4) p1.20, 9 (2)
st-213 2 4 B(4) p1.22, 14 (3)
st-35 1 1 B(1) p1.22-1, 14(1)
st-167 1 1 y(1) p1.5-1, 10-8(1)
st-18 1 1 B(1) p1.22, 14(1)
st-60 1 1 B(1) p1.21, 16(1)
a pora type=vr1, vr2.
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